Answers are grounded in this paper and cite their sources.
Real-world evidence demonstrates antiviral activity of ensitrelvir in hemodialysis patients with COVID-19, suggesting potential clinical benefits.
Patients on maintenance hemodialysis are highly vulnerable to severe COVID-19. Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor approved in Japan for COVID-19, has not been evaluated in patients on hemodialysis. Here we report real-world evidence on pharmacokinetics, antiviral activity and clinical effectiveness of ensitrelvir in patients on hemodialysis.
No takes yet. Share an insight, caveat, or question.
Kitamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: